CA3184878A1 - Sars-cov-2 and influenza combination vaccine - Google Patents

Sars-cov-2 and influenza combination vaccine

Info

Publication number
CA3184878A1
CA3184878A1 CA3184878A CA3184878A CA3184878A1 CA 3184878 A1 CA3184878 A1 CA 3184878A1 CA 3184878 A CA3184878 A CA 3184878A CA 3184878 A CA3184878 A CA 3184878A CA 3184878 A1 CA3184878 A1 CA 3184878A1
Authority
CA
Canada
Prior art keywords
cov
influenza
sars
vaccine
covid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3184878A
Other languages
English (en)
French (fr)
Inventor
Agata Fazio
Emanuele MONTOMOLI
Kaspar BANZIGER
Carlos QUINTO
Reinhard Gluck (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spicona Inc
Original Assignee
Spicona Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spicona Inc filed Critical Spicona Inc
Publication of CA3184878A1 publication Critical patent/CA3184878A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3184878A 2020-07-07 2021-07-07 Sars-cov-2 and influenza combination vaccine Pending CA3184878A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2010425.3A GB2596820A (en) 2020-07-07 2020-07-07 Combination vaccine
GB2010425.3 2020-07-07
PCT/IB2021/056102 WO2022009121A1 (en) 2020-07-07 2021-07-07 Sars-cov-2 and influenza combination vaccine

Publications (1)

Publication Number Publication Date
CA3184878A1 true CA3184878A1 (en) 2022-01-13

Family

ID=72050416

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3184878A Pending CA3184878A1 (en) 2020-07-07 2021-07-07 Sars-cov-2 and influenza combination vaccine

Country Status (15)

Country Link
US (1) US20230256085A1 (enExample)
EP (1) EP4178612A1 (enExample)
JP (1) JP2023533772A (enExample)
KR (1) KR20230049084A (enExample)
CN (1) CN117957016A (enExample)
AR (1) AR122899A1 (enExample)
AU (1) AU2021303789A1 (enExample)
BR (1) BR112023000323A2 (enExample)
CA (1) CA3184878A1 (enExample)
CO (1) CO2023001072A2 (enExample)
GB (1) GB2596820A (enExample)
IL (1) IL299735A (enExample)
MX (1) MX2023000411A (enExample)
TW (1) TW202207979A (enExample)
WO (1) WO2022009121A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
US11576961B2 (en) 2017-03-15 2023-02-14 Modernatx, Inc. Broad spectrum influenza virus vaccine
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
US20230416309A1 (en) * 2020-10-23 2023-12-28 Jiangsu Provincial Center For Disease Control And Prevention (Public Health Research Institute Of Ji Fusion protein and application thereof
CN113293145B (zh) * 2021-02-01 2022-08-26 上海青赛生物科技有限公司 一种麻疹病毒活载体新冠疫苗
EP4322994A1 (en) * 2021-04-14 2024-02-21 ModernaTX, Inc. Influenza-coronavirus combination vaccines
JP2024516309A (ja) * 2021-05-05 2024-04-12 ノババックス，インコーポレイテッド コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法
CN113462700B (zh) * 2021-05-07 2023-06-09 杨光华 SARS-CoV-2线性DNA疫苗
CN114717251B (zh) * 2021-08-24 2023-03-24 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2原始株和Beta株的腺病毒载体疫苗
WO2023047419A1 (en) * 2021-09-24 2023-03-30 Bharat Biotech International Limited A vaccine for coronavirus and influenza virus, and method for preparation thereof
CN113755644B (zh) * 2021-09-24 2024-05-03 中国科学院武汉病毒研究所 一种检测新型冠状病毒Alpha和Delta突变体试剂盒及应用
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN114891817A (zh) * 2022-04-15 2022-08-12 华南理工大学 一种多聚肽及其制备方法与应用
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024174012A1 (pt) * 2023-02-24 2024-08-29 Instituto Butantan Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal
CN115992101B (zh) * 2023-03-22 2023-07-28 深圳市卫光生物制品股份有限公司 一种流感病毒裂解疫苗原液的制备方法
CN116350769B (zh) * 2023-03-31 2024-07-19 北京吉诺卫生物科技有限公司 一种新冠病毒和流感病毒的联合疫苗、其制备方法与应用
CN116327910B (zh) * 2023-03-31 2024-05-03 北京吉诺卫生物科技有限公司 一种新冠病毒、流感病毒和/或rsv的联合疫苗、其制备方法与应用
EP4710936A4 (en) * 2023-05-10 2026-08-12 Univ Hokkaido Nat Univ Corp COMBINED VACCINE FOR THE PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS
CN118141906B (zh) * 2024-02-22 2025-08-22 安徽智飞龙科马生物制药有限公司 一种新冠流感联合疫苗及其制备方法
WO2026123991A1 (zh) * 2024-12-12 2026-06-18 中国人民解放军军事科学院军事医学研究院 一种含有脂肪酸化修饰的SpyCatcher蛋白的免疫组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
CN1775287A (zh) * 2004-11-16 2006-05-24 北京科兴生物制品有限公司 一种sars流感二价联合疫苗及其制备工艺
GB0822001D0 (en) * 2008-12-02 2009-01-07 Glaxosmithkline Biolog Sa Vaccine
WO2012104820A1 (en) * 2011-02-04 2012-08-09 Pfizer Inc. Compositions for canine respiratory disease complex
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
US20130236494A1 (en) * 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
CN107961371B (zh) * 2017-04-19 2020-08-11 武汉博沃生物科技有限公司 季节流感-rsv联合疫苗及其制备方法和应用
CN110974950B (zh) * 2020-03-05 2020-08-07 广州恩宝生物医药科技有限公司 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗
CN111217917B (zh) * 2020-02-26 2020-10-23 康希诺生物股份公司 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法
CN111218458B (zh) * 2020-02-27 2020-11-20 珠海丽凡达生物技术有限公司 编码SARS-CoV-2病毒抗原的mRNA和疫苗及疫苗的制备方法

Also Published As

Publication number Publication date
IL299735A (en) 2023-03-01
CO2023001072A2 (es) 2023-06-20
KR20230049084A (ko) 2023-04-12
WO2022009121A1 (en) 2022-01-13
TW202207979A (zh) 2022-03-01
AR122899A1 (es) 2022-10-12
US20230256085A1 (en) 2023-08-17
GB2596820A (en) 2022-01-12
MX2023000411A (es) 2023-04-10
AU2021303789A1 (en) 2023-02-16
EP4178612A1 (en) 2023-05-17
GB202010425D0 (en) 2020-08-19
JP2023533772A (ja) 2023-08-04
CN117957016A (zh) 2024-04-30
BR112023000323A2 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
US20230256085A1 (en) Combination vaccine
Mezhenskaya et al. M2e-based universal influenza vaccines: a historical overview and new approaches to development
US20240108715A1 (en) 2019-ncov (sars-cov-2) vaccine
ES2858315T3 (es) Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
AU2022204267A1 (en) Vaccine compositions
KR101983989B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
US11478543B1 (en) Coronavirus disease (COVID-19) vaccine
JP2023524990A (ja) ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用
JP2023519837A (ja) コロナウイルスを処置するためのワクチン組成物
US20240350622A1 (en) Vaccine Antigen
US12397050B2 (en) Universal mammalian influenza vaccine
CA2828068C (en) Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
EP3202780A1 (en) Fusion protein comprising the n protein of a virus of the pneumovirinae subfamily
WO2026030724A1 (en) Sars-cov-2 vaccine
JP2025539418A (ja) 新規ナノ粒子足場を含有するワクチン
HK40070461B (zh) 冠状病毒疫苗组合物、方法及其使用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240708

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241024

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241024

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250707

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250707

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250707

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250707

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250714

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250714

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250912

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250912

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250912